Lyell Immunopharma, Inc. (LYEL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 21, 2025

$0.57

P/E Ratio

N/A

Market Cap

$166.21M

Loading...
Description

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Metrics

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerLYEL
  • Price$0.5689-1.15%

Trading Information

  • Market cap$166.21M
  • Float51.62%
  • Average Daily Volume (1m)823,721
  • Average Daily Volume (3m)1,582,405
  • EPS-$0.80

Company

  • Revenue$0.06M
  • Rev growth (1yr)36.00%
  • Net income-$44.58M
  • Gross margin-13,664.71%
  • EBITDA margin-137,044.12%
  • EBITDA-$46.60M
  • EV-$28.27M
  • EV/Revenue-448.66
  • P/EN/A
  • P/S2,314.51
  • P/B0.28
Documents